Risk Giving Rise to Substantial Doubt About the Going Concern Assumption
First written in FY2018-Q2. 19 of 21 entries say "Restated". Latest entry: 2026-08-13.
The whole theme swung hardest in 2020: 30 of 71 companies on the "Worse" side.
41 other companies' latest entry also says "Restated".
- FY2025-H1WorsenedAnnual report
「The Company continues to incur operating losses and negative operating cash flow because the recovery in revenue from the cell processing business has remained insufficient following a sharp decline caused by changes in the environment surrounding the cancer immunotherapy market, while expenditures associated with progress in developing its own products in the regenerative medicine products business continue to increase, creating a risk that substantial doubt may arise regarding the going-concern assumption.」
The Company added language stating that the recovery remained insufficient even after the sharp decline in revenue from the cell processing business, providing a clearer description of the going-concern risk arising from continuing operating losses and negative operating cash flow. - FY2024-Q2RestatedAnnual report
「Operating losses and negative operating cash flow have continued to occur, and risks exist that could raise substantial doubt about the company's ability to continue as a going concern.」
While disclosing going-concern risk arising from continuing operating losses and negative operating cash flow, the Company maintains its determination, taking its financial position and other factors into account, that no material uncertainty exists. - FY2023RestatedAnnual report
「At present, the Company maintains a stable cash position by securing funds through the steady implementation of structural reforms and financing, including funds for regenerative medicine product development expenses raised through the issuance of the 14th and 15th stock acquisition rights in June 2019, the 16th in July 2020, the 17th in September 2020, the 18th in September 2021 and the 19th in March 2023. Accordingly, it has determined that there are no concerns regarding its cash position for the foreseeable future.」
While disclosing recurring operating losses and negative operating cash flow, the Company continues to determine, based on its financing and cash on hand, that no material uncertainty exists. - FY2023-Q3RestatedAnnual report
「The Company has continuously incurred operating losses and negative operating cash flow because of a sharp decline in sales in the cell-processing business accompanying changes in the environment for the cancer immunotherapy market, as well as accumulating expenditures associated with progress in the development of its own products in the regenerative medicine products business. Consequently, there is a risk that significant uncertainty may arise regarding the going-concern assumption.」
The Company continues to disclose going-concern risk against the backdrop of recurring operating losses, negative operating cash flow and other factors. Meanwhile, it maintains its determination, taking its financial position and other factors into account, that no material uncertainty exists. - FY2023-Q2RestatedAnnual report
「The Company has continuously incurred operating losses and negative operating cash flow because of a sharp decline in sales in the cell-processing business accompanying changes in the environment for the cancer immunotherapy market, as well as accumulating expenditures associated with progress in the development of its own products in the regenerative medicine products business. Consequently, there is a risk that significant uncertainty may arise regarding the going-concern assumption.」
The Company continues to disclose going-concern risk against the backdrop of a sharp decline in revenue, product development expenditures, operating losses and negative operating cash flow. Meanwhile, it maintains its determination, taking its financial position and other factors into account, that no material uncertainty exists. - FY2023-Q1RestatedAnnual report
「The Company has continuously incurred operating losses and negative operating cash flow because of a sharp decline in sales in the cell-processing business accompanying changes in the environment for the cancer immunotherapy market, as well as accumulating expenditures associated with progress in the development of its own products in the regenerative medicine products business. Consequently, there is a risk that significant uncertainty may arise regarding the going-concern assumption.」
The Company continues to disclose going-concern risk against the backdrop of recurring operating losses, negative operating cash flow and other factors. Meanwhile, it maintains its determination, taking its financial position into account, that no material uncertainty exists. - FY2022-Q3RestatedAnnual report
「The Company has continuously incurred operating losses and negative operating cash flow because of a sharp decline in sales in the cell-processing business accompanying changes in the environment for the cancer immunotherapy market, as well as accumulating expenditures associated with progress in the development of its own products in the regenerative medicine products business. Consequently, there is a risk that significant uncertainty may arise regarding the going-concern assumption.」
The Company continues to disclose going-concern risk against the backdrop of operating losses, negative operating cash flow and other factors. Meanwhile, it maintains its determination that no material uncertainty exists. - FY2022-Q2RestatedAnnual report
「The Company has continuously incurred operating losses and negative operating cash flow because of a sharp decline in sales in the cell-processing business accompanying changes in the environment for the cancer immunotherapy market, as well as accumulating expenditures associated with progress in the development of its own products in the regenerative medicine products business. Consequently, there is a risk that significant uncertainty may arise regarding the going-concern assumption.」
The Company continues to disclose going-concern risk against the backdrop of a sharp decline in revenue from the cell processing business, product development expenditures, operating losses and negative operating cash flow. Meanwhile, it has determined, taking financing and other factors into account, that no material uncertainty exists. - FY2022-Q1RestatedAnnual report
「The Company has continuously incurred operating losses and negative operating cash flow because of a sharp decline in sales in the cell-processing business accompanying changes in the environment for the cancer immunotherapy market, as well as accumulating expenditures associated with progress in the development of its own products in the regenerative medicine products business. Consequently, there is a risk that significant uncertainty may arise regarding the going-concern assumption.」
The Company continues to disclose going-concern risk against the backdrop of operating losses, negative operating cash flow and other factors. Meanwhile, it maintains its determination, taking financing and its cash balance into account, that no material uncertainty exists. - FY2021-Q3RestatedAnnual report
「The Company has continuously incurred operating losses and negative operating cash flow because of a sharp decline in sales in the cell-processing business accompanying changes in the environment for the cancer immunotherapy market, as well as accumulating expenditures associated with progress in the development of its own products in the regenerative medicine products business. Consequently, there is a risk that significant uncertainty may arise regarding the going-concern assumption.」
The Company continues to disclose going-concern risk against the backdrop of recurring operating losses, negative operating cash flow and other factors. Meanwhile, it maintains its determination that no material uncertainty exists. - FY2021-Q2RestatedAnnual report
「The Company has continuously incurred operating losses and negative operating cash flow because of a sharp decline in sales in the cell-processing business accompanying changes in the environment for the cancer immunotherapy market, as well as accumulating expenditures associated with progress in the development of its own products in the regenerative medicine products business. Consequently, there is a risk that significant uncertainty may arise regarding the going-concern assumption.」
The Company continues to disclose going-concern risk against the backdrop of a sharp decline in revenue, product development expenditures, operating losses and negative operating cash flow. Meanwhile, it has determined, taking financing and other factors into account, that no material uncertainty exists. - FY2021-Q1RestatedAnnual report
「We have determined that no material uncertainty exists regarding the going-concern assumption.」
While disclosing the risk of continuing operating losses and negative operating cash flow, the Company continues to determine, based on a comprehensive review of its structural reforms, financing and cash balance, that no material uncertainty exists. - FY2020-Q3RestatedAnnual report
「The Company has continuously incurred operating losses and negative operating cash flow because of a sharp decline in sales in the cell-processing business accompanying changes in the environment for the cancer immunotherapy market, as well as accumulating expenditures associated with progress in the development of its own products in the regenerative medicine products business. Consequently, there is a risk that significant uncertainty may arise regarding the going-concern assumption.」
The Company continues to disclose going-concern risk against the backdrop of a sharp decline in revenue, product development expenditures, operating losses and negative operating cash flow. It has determined that no material uncertainty exists as a result of the measures being implemented. - FY2020-Q1RestatedAnnual report
「The Company has continuously incurred operating losses and negative operating cash flow because of a sharp decline in sales in the cell-processing business accompanying changes in the environment for the cancer immunotherapy market, as well as accumulating expenditures associated with progress in the development of its own products in the regenerative medicine products business. Consequently, there is a risk that significant uncertainty may arise regarding the going-concern assumption.」
The Company continues to disclose going-concern risk against the backdrop of a sharp decline in revenue, product development expenditures, operating losses and negative operating cash flow. - FY2019-Q3RestatedAnnual report
「The Company has continuously incurred operating losses and negative operating cash flow because of a sharp decline in sales in the cell-processing business accompanying changes in the environment for the cancer immunotherapy market, as well as accumulating expenditures associated with progress in the development of its own products in the regenerative medicine products business. Consequently, there is a risk that significant uncertainty may arise regarding the going-concern assumption.」
The Company continues to disclose going-concern risk against the backdrop of a sharp decline in revenue, increasing product development expenditures, operating losses and negative operating cash flow. Meanwhile, it has determined that no material uncertainty exists as a result of the measures being implemented. - FY2019-Q2RestatedAnnual report
「The Company has continuously incurred operating losses and negative operating cash flow because of a sharp decline in sales in the cell-processing business accompanying changes in the environment for the cancer immunotherapy market, as well as accumulating expenditures associated with progress in the development of its own products in the regenerative medicine products business. Consequently, there is a risk that significant uncertainty may arise regarding the going-concern assumption.」
The Company continues to disclose going-concern risk against the backdrop of a sharp decline in revenue, increasing product development expenditures, operating losses and negative operating cash flow. - FY2019-Q1RestatedAnnual report
「The Company has continuously incurred operating losses and negative operating cash flow because of a sharp decline in sales in the cell-processing business accompanying changes in the environment for the cancer immunotherapy market, as well as accumulating expenditures associated with progress in the development of its own products in the regenerative medicine products business. Consequently, there is a risk that significant uncertainty may arise regarding the going-concern assumption.」
The Company continues to disclose going-concern risk against the backdrop of a sharp decline in revenue, increasing product development expenditures, operating losses and negative operating cash flow. Meanwhile, it states that no material uncertainty exists as a result of the measures being implemented. - FY2018-Q3RestatedAnnual report
「The Group continues to incur operating losses and negative operating cash flows because, in addition to a sharp decline in cell-processing revenue caused by changes in the cancer immunotherapy market, expenditures associated with progress in developing proprietary products in the regenerative medical products business are continuing to accumulate. As a result, a risk exists that may raise substantial doubt about the going concern assumption.」
The Company continues to disclose going-concern risk against the backdrop of a sharp decline in revenue, increasing product development expenditures, operating losses and negative operating cash flow. Meanwhile, it has determined that no material uncertainty exists as a result of the measures being implemented. - FY2018-Q2First statedAnnual report
「The Group continues to incur operating losses and negative operating cash flows because, in addition to a sharp decline in cell-processing revenue caused by changes in the cancer immunotherapy market, expenditures associated with progress in developing proprietary products in the regenerative medical products business are continuing to accumulate. As a result, a risk exists that may raise substantial doubt about the going concern assumption.」
The Company explicitly identifies going-concern risk against a backdrop of sharply lower revenue, rising product-development expenditures, operating losses and negative operating cash flows.